Quick Answer
ORAMED PHARMACEUTICALS INC. reported Research And Development Expense of $6.38 million for the year ending 2025.
- ORAMED PHARMACEUTICALS INC. showed an increase of +0.9% in Research And Development Expense from 2024 to 2025.
- This data is from ORAMED PHARMACEUTICALS INC.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), ORAMED PHARMACEUTICALS INC.'s Research And Development Expense has grown by 450.4%.
- Historical annual values: Fiscal year 2025: $6.38 million | Fiscal year 2024: $6.32 million | Fiscal year 2023: $8.97 million | Fiscal year 2022: $27.64 million | Fiscal year 2021: $20.99 million | Fiscal year 2020: $10.24 million | Fiscal year 2019: $13.52 million | Fiscal year 2018: $11.98 million | Fiscal year 2017: $10.28 million | Fiscal year 2016: $7.71 million | Fiscal year 2015: $4.78 million | Fiscal year 2014: $3.28 million | Fiscal year 2013: -$2.27 million | Fiscal year 2012: $1.68 million | Fiscal year 2011: $1.16 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: